{"id":"bromhexine-and-spironolactone","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bromhexine breaks down mucopolysaccharides in sputum to reduce mucus viscosity and improve clearance, while spironolactone blocks aldosterone receptors in the collecting duct to promote sodium and water excretion while retaining potassium. This combination may be investigated for conditions involving both respiratory secretion management and fluid/electrolyte balance, though the rationale for combining these agents in a single formulation is uncommon.","oneSentence":"Bromhexine acts as a mucolytic agent to thin respiratory secretions while spironolactone is a potassium-sparing diuretic and aldosterone antagonist.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:27.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory conditions with excessive mucus production (bromhexine component)"},{"name":"Fluid retention or hypertension (spironolactone component)"}]},"trialDetails":[{"nctId":"NCT04424134","phase":"PHASE3","title":"BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization","status":"UNKNOWN","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2020-05-16","conditions":"COVID 19","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bromhexine and Spironolactone","genericName":"Bromhexine and Spironolactone","companyName":"Lomonosov Moscow State University Medical Research and Educational Center","companyId":"lomonosov-moscow-state-university-medical-research-and-educational-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromhexine acts as a mucolytic agent to thin respiratory secretions while spironolactone is a potassium-sparing diuretic and aldosterone antagonist. Used for Respiratory conditions with excessive mucus production (bromhexine component), Fluid retention or hypertension (spironolactone component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}